About the Event
Targeted Immunotherapy has the promise to transform cancer treatment. Currently, however, only a minority of patients achieve long-lasting benefit from immunotherapy because tumor antigens adapt and hide from therapies over time.
BryoLogyx is developing bryostatin, a platform of tumor and antigen stimulating drugs that improve the efficacy of cancer immunotherapies. Bryostatin makes the tumors more “visible” to therapeutics by increasing the expression of cell surface antigens. This makes tumors easier to target and kill. Bryostatin has been the subject of numerous clinical trials in more than 1,100 patients and has an established safety profile.
Join our webinar with Bryologyx Founder and CEO, Thomas Loarie to hear more about the science behind bryostatin and why the company attained the exclusive license for use in cancer, inflammatory, autoimmune, and infectious diseases.